abstract | Atrial fibrillation (AF) is a growing clinical problem associated with increased morbidity and mortality. Currently available antiarrhythmic drugs (AADs), although highly effective in acute cardioversion of paroxysmal AF, are generally only moderately successful in long-term maintenance of sinus rhythm. The use of AADs is often associated with an increased risk of ventricular proarrhythmia, extracardiac toxicity, and exacerbation of concomitant diseases such as heart failure. AF is commonly associated with intracardiac and extracardiac disease, which can modulate the efficacy and safety of AAD therapy. In light of the multifactorial intracardiac and extracardiac causes of AF generation, current development of anti-AF agents is focused on modulation of ion channel activity as well as on upstream therapies that reduce structural substrates. The available data indicate that multiple ion channel blockers exhibiting potent inhibition of peak I Na with relatively rapid unbinding kinetics, as well as inhibition of late I Na and I Kr , may be preferable for the management of AF when considering both safety and efficacy.
Introduction
atrial fibrillation (aF) is the most commonly encoun tered sustained arrhythmia, affecting an estimated 2.3 million people in the us alone.
1 advancing age is a major risk factor for aF and the prevalence of this con dition is rising at an alarming rate with ageing of the popula tion.
1 of the two principal options for the manage ment of aF, rhythm control-which aims to restore and maintain sinus rhythm-is believed to be preferable to rate control, in which ventricular rate is regulated while the atria continue to fibrillate.
1-3 However, currently available approaches for rhythm control have impor tant limitations, which are discussed below, making rate control preferable in some cases, particularly in older patients with relatively few symptoms of aF.
rhythm control of aF can be achieved with anti arrhythmic drugs (aaDs), catheter ablation techniques, or electrical cardioversion. aaDs are often successfully used to maintain sinus rhythm following catheter abla tion or cardioversion.
4 most aaDs currently available for rhythm control of aF have poor safety profiles and in adequate longterm efficacy, making longterm pharmacologic rhythm control in patients with aF a challenge. 5, 6 the results of a number of multicenter, randomized, and prospective clinical trials, includ ing aFFirm, 7 and the aFCHF, 8 raCe, 9 and PiaF 10 studies, suggest that rhythm control strategy with aaDs is not superior to rate control in terms of survival, and may be associated with an increase in rate of hospitali zation. adverse effects of aaDs, such as ventricular pro arrhythmia and extra cardiac toxicity, are likely to negate the limited ability of these agents to maintain sinus rhythm. the post-hoc analy sis of the aFFirm data showed that patients maintained in sinus rhythm had a better survival rate than those in whom aF persisted.
11
mounting evidence indicates that for some aF cases-particularly relatively young (<65 years of age) symptomatic patients-catheter ablation is superior to currently available aaDs for longterm maintenance of sinus rhythm.
12,13 However, despite progress in catheter ablation technologies and improvements in the success of these techniques, aaDs remain firstline therapy for rhythm control of aF 1 and are expected to do so for the foreseeable future.
aF is commonly associated with atrial electrical and structural abnormalities as well as with a constellation of intracardiac and extracardiac diseases, including heart failure, hypertension, coronary artery disease, myocardial infarction, and valvular heart defects, which can develop independently of aF but may promote and be aggra vated by the arrhythmia. each of these aFassociated abnormalities and diseases, as well as numerous medi ating factors of these disorders, can also be pharmaco logical targets for aF treatment and may alter the safety and antiaF efficacy of aaD therapy. Development of antiaF medications, therefore, is currently focused on modulation of ion channel activity as well as on upstream therapies that target these intracardiac and extracardiac factors that induce or promote structural remodeling (Figure 1 ). other preclinical investigations are directed at pharmacological modulation of gap junctions and intracellular calcium activity. in this review, we discuss current and novel pharmacological approaches to rhythm control in patients with aF.
Modulation of ion channel activity
most aaDs in current clinical use exert their antiaF actions via inhibition of cardiac ion channels, particu larly during acute administration (table 1) . Chronic treatment can additionally remodel ion channel expres sion, 14 cause degradation of specific ion channels (for example, the ultrarapid delayed rectifier potassium current [I Kur ] as reported with quinidine 15 ), or influence atrial electrical and structural remodeling, as observed with amiodarone. 16, 17 antiaF drugs can be very effective in the short term, with up to 80-90% efficacy for the ter mination of paroxysmal aF and some forms of persistent aF. [18] [19] [20] However, these agents are generally only moder ately effective for longterm rhythm control of paroxys mal aF, and even less so in the case of persistent aF.
1 the longterm (1-1.5 years) efficacy of amiodarone, which is arguably the best available aaD for the maintenance of sinus rhythm, ranges from 34% to 65%. 12, 21 the principal complication of all antiaF drugs is that they are associated with an increased risk of life threatening ventricular arrhythmias, induction of multiorgan toxicity,
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atrial-selective ion channel block the atrialselective approach to the treatment of aF was conceived with the aim of reducing the risk of ventricu lar arrhythmias. the channels responsible for the I Kur , the acetylcholineregulated inward rectifying potassium current (I K-ACh ), and the constitutively active (Ca)I K-Ach (which does not require acetylcholine or muscarinic receptors for activation) are present in atria, but largely absent from the ventricles. these channels are, therefore, commonly referred to as being atrialspecific. 29, 30 while this strategy is attractive in theory, the available data indicate that blockade of I Kur alone might not effectively suppress aF. [31] [32] [33] indeed, when administered at concen trations that effectively suppress aF, currently available I Kur blockers potently inhibit other currents as well. For example, vernakalant and aZD7009 also block the early sodium current (I Na ) and ave0118 also blocks the tran sient outward potassium current (I to ), I KACh , CaI K-ACh , and I Na . [34] [35] [36] [37] [38] the antiaF actions of aZD7009 and vernakalant appear to be largely the result of inhibition of I Na rather than I Kur . 32 aZD7009 reduces excitability and conduc tion velocity preferentially in the atria of dogs in vivo, 39 indicating atrialselective sodiumchannel block. while a number of other purported I Kur blockers have been shown to produce atrialselective effective refractory period (erP) prolongation and to suppress experimental aF, 40 whether pure I Kur block can effectively suppress aF has yet to be demonstrated. 30, 33 selective inhibition of I Kur neither prevents nor terminates acetylcholinemediated aF in canine atria. 41 notably, I Kur density is progressively reduced with acceleration of activation rate; 42 there fore, the contribution of this current in aF may be rela tively small. However, under conditions associ ated with triangu lation of atrial action potential morphology (elec trical remodeling or rapid activation rates), I Kur blockers promote prolongation of action potential duration at 90% repolarization (aPD 90 ). 43 I Kur density has also been reported to be reduced in cells isolated from the atria of patients with chronic aF. 37, 44 By contrast to remodeled atria, where I Kur block slightly prolongs aPD 90 , selec tive I Kur inhibition abbreviates aPD 90 in healthy atria (Figure 2) . 41, 45 this finding could explain the occurrence of aF with I Kur inhibition in 'healthy' canine atria 41 and the association between aF and a mutation in KCNA5, the gene that encodes the α subunit of the I Kur channel. 46 vagal activity can contribute to the initiation of paroxys mal aF, 47, 48 and so blocking parasympathetic acti vity could help maintain sinus rhythm in these patients. I KACh block with tertiapinQ prolongs atrial aPD and suppresses aF in experimental models. 49, 50 interestingly, CaI KACh is only marginally present in healthy non fibrillating human or canine atria and is significantly increased in the atria of patients with chronic aF and in canine tachycardia remodeled atria, 49, [51] [52] [53] indicating that this current is not only atrialspecific, but is also a pathologyspecific target. 54 at present, there are no available drugs that selectively block CaI KACh .
atrial-selective multiple ion channel block several cardiac ion channels, including fast I Na sodium channels 30, 55 and I Kr potassium channels, 56-64 respond in an atrialselective or predominant manner when blocked with specific drugs, despite being present in both atria and ventricles. in canine coronaryperfused cardiac preparations, atrialselective or predominant I Na blockers, such as amiodarone (longterm treatment) and ranolazine, effectively suppress aF with little or no effects in the ventricles. 31, 55, 63, 65 ranolazine and amio darone exert these actions by atrialselective or atrial predominant depression of I Na -dependent parameters leading to increased diastolic threshold of excitation and induction of postrepolarization refractoriness (Figures 3 and 4) . 55, 63, 66, 67 in superfused pulmonary vein preparations, both ranolazine and longterm amiodarone also effectively suppress intracellular calciumdependent delayed (DaD) and late phase 3 early after depolarization (eaD)induced triggered activity. 66, 67 aZD7009 is also an atrialselective I Na blocker. 39 although the clinical antiaF efficacy of amiodarone, ranolazine, and aZD7009 has been documented, 19, 25, [68] [69] [70] the degree to which the effi cacy of these multiple ion channel blockers depends on their potency to depress sodiumchanneldependent parameters remains to be elucidated.
it should be emphasized that the nature and degree of atrial selectivity of aaDs observed in normal hearts may be different in remodeled hearts or those associated with various pathologies, including myocardial infarc tion, long Qt syndrome, heart failure, and hypertrophy. the pharmaco logical responses to sodiumchannel and potassiumchannel blockers can be very different, and even opposite (Figure 2 ), in healthy versus diseased atria and ventricles; both augmentation and reduction in blocking efficacy have been reported. 32, 45, 71 these altered substrates and pharmacological sensitivities could explain why atrialselective agents (ranolazine, ave0118, chronic amiodarone) can successfully suppress ventricu lar arrhythmias encountered under pathophysiological conditions. 24, 68, 72 a number of factors are likely to contribute to the atrial selectivity of I Na blockers, including a more depolarized resting membrane potential (rmP), more negative half inactivation voltage (v 0.5 ), and more gradual phase 3 of the f o c u s o N at r i a l f i B r i l l at i o N action potential in atrial cells as compared with ventricu lar cells (Figure 3) . 32, 55, 73 as a consequence, a large pro portion of sodium channels are inactivated at the normal rmP in atrial cells. the fraction of resting channels is, therefore, smaller in atrial cells than in ventricular cells at rmP. atrial cells show a greater accumulation of use dependent sodiumchannel block, because much of the recovery from sodiumchannel block commonly occurs during the resting state of the channel. 74, 75 rapid kinetics of recovery from inactivation is thought to contribute to the atrial selectivity of sodiumchannel blockers. Drugs, such as propafenone, that exhibit slow dissociation from the sodium channel show little or no atrial selectivity, whereas agents that dissociate rapidly, such as ranolazine and amiodarone, tend to be highly atrialselective in their inhibition of I Na dependent parameters. 55, 76 our current understanding of the mechanisms of atrial selectivity of I Na blockers, as well as potential applications of atrial selective I Na block for rhythm control of aF, have been discussed in more detail eslewhere. 31, 32, 77 mechanisms by which depression of I Na by drugs with rapid unbind ing kinetics lead to aF termination are discussed in an elegant study by Comtois and colleagues. 78 selective inhibition of I Kr prolongs aPD and erP to a greater extent in the atria than in the ventricles at both normal and rapid heart rates ( Figure 4) . [56] [57] [58] [59] [60] [61] [62] atrialpredominant prolongation of aPD and erP by ranolazine and chronic amiodarone (both I Kr blockers) is thought to contribute to their atrialselective, use dependent inhibition of sodiumchanneldependent parameters in the atria by causing greater abbreviation of the diastolic interval (Figure 4) . much of the recovery of sodium channels from inactivation occurs during the diastolic interval and curtailment of this interval pro motes accumulation of I Na block. under bradycardic conditions or following long pauses, however, it is the ventricles rather than atria that develop substantial aPD prolongation, eaDs, and tdP with selective I Kr inhibi tion.
79,80 the proarrhythmic effects of I Kr block can be counteracted with a concomitant block of late I Na. in remodeled atria, in which aPD is abbreviated, prolonga tion of aPD 90 secondary to I Kur block can promote accu mulation of I Na block preferentially by reducing diastolic interval in the atria but not in ventricles. 32 the reduced ability of I Kr block to prolong aPD in remodeled atria can be overcome with additional inhibition of I Kur /I to . 81 Practical clinical experience indicates that multi ple ion channel blockers that can block I Na with rapid dissoci ation kinetics are generally better suited for rhythm control of aF than are selective ion channel blockers, because the former have a more favorable risk:benefit ratio. 32 with the exception of I Kr blockers, such as dofetilide, currently used aaDs (amiodarone, droneda rone, flecainide, propafenone) and promis ing investigational aaDs (vernakalant and aZD7009) inhibit multiple ion channels. notably, selective inhibi tion of I Na , which at present can be achieved only with I Na blockers with rapid binding and unbinding kinetics (for example, lidocaine and mexiletine), is not very effective in the clinical manage ment of aF. 1 several antiaF agents, including amiodarone, drone darone, vernakalant, and ranolazine, are effective in the clinic and do not, or only rarely, produce ventricular proarrhythmia. these relatively safe aaDs have two fea tures in common; firstly they all inhibit I Na with relatively rapid kinetics and, secondly, they all also block I Kr . as dis cussed, rapidly dissociating I Na blockers tend to be atrial selective, whereas slowly dissociating blockers are not. 32 these characteristics coupled with the ability of these drugs to inhibit late I Na , which keeps the effects of their I Kr block in check, adds to their electrical safety profile. late I Na inhibition plays a key role in the suppression of ventricular arrhythmias in a variety of pathological con ditions, such as long Qt syndrome, acute ischemia, and heart failure. [82] [83] [84] slowly dissociating I Na blockers, which also block late I Na , 85 promote arrhythmogenesis in struc turally compromised ventricles because they slow con duction and induce unidirectional block, thus providing the substrate for the development of reentry. 23 in summary, the available data indicate that multiple ion channel blockers exhibiting potent inhibition of fast I Na with relatively rapid unbinding kinetics, as well as inhibition of late I Na and I Kr seem to be best suited for the management of aF. the addition of I Kur block to this cocktail is theorized to increase atrial selecti vity and antiaF ability in remodeled atria. 32 the long term adverse effects of aaDs are difficult to predict, as shown by the results of Cast, 23 and anDromeDa trials. 22 However, agents, such as droneda rone and ranolazine, that have the above ion channel profile seem to be relatively safe in the longterm for some, 87, 88 but perhaps not all, 22 aF pathologies.
improved derivatives of existing drugs another approach for the development of new drugs involves modification of molecules that have demon strated antiaF efficacy. many aaDs in current use are derivatives of existing drugs; for example, flecainide and propafenone stem from procainamide and propranolol, respectively. one notable example of this approach is dronedarone, which was approved by the FDa in July 2009 and is an amiodarone derivative lacking the iodine moiety believed to be responsible for the multiorgan toxicity associated with amiodarone use. Dronedarone has been found to be significantly more effective than placebo in maintaining sinus rhythm in patients with aF, and is largely free of extracardiac toxicity. 89 Dronedarone also has ratecontrol properties, 89, 90 and aaDs that have combined rhythmcontrol and ratecontrol effects may be of particular interest in future aaD development. the antiaF efficacy of dronedarone, however, appears to be inferior to that of amiodarone. 88 in the landmark, randomized placebocontrolled study, atHena, 91 dronedarone substantially reduced incidence of cardiac hospitalization and cardiovascularrelated death in patients with aF. 91 of the enrolled patients, 21% had nYHa class ii or iii chronic heart failure, 12% had an lv ejection fraction of less than 45%, and 60% had coronary artery disease. 91 the amelioration of several comorbidi ties, including reduced incidence of aF, stroke, and acute coronary syndrome and a decrease in blood pressure, was observed with the use of dronedarone in atHena. 90, 92 these dronedaronerelated positive outcomes are likely to be interrelated and contribute to the decrease in cardiovascularrelated hospitalization and death. 91, 92 However, allcause mortality was not statistically signifi cantly reduced by dronedarone use in atHena (5% for dronedarone versus 6% for placebo, P = 0.18). 91 in another large trial (anDromeDa), 22 dronedarone was associ ated with increased mortality in patients with severe heart failure and lv systolic dysfunction (nYHa class iii and iv), which was likely to be the result of worsening chronic heart failure. whether the increase in mortality in anDromeDa was related to dronedarone itself, or to unrelated confounding factors, remains unknown. the initially postulated hypothesis accounting for the increase in mortality in anDreomeDa (that is, discontinuation of treatment with angiotensinconvertingenzyme [aCe] inhibitors because of elevation in serum creatinine level) remains an issue of debate. 88 a negative inotropic effect of dronedarone resulting from inhibition of I Ca-L 93 could have contributed to worsening of severe heart failure, leading to increased mortality. 88 other examples of efforts to improve existing aaDs include aZD1305 and ave1231, which are derivatives of aZD7009 and ave0118, respectively. 94, 95 aZD7009 has been found to be effective in acute cardioversion of both paroxysmal and persistent aF, with a small risk for induction of ventricular arrhythmias. 19, 70 although ave0118 effectively suppresses aF in several experimen tal aF models, 36, 38 its clinical efficacy turned out to be dis appointing and its clinical use for longterm management of aF is limited by firstpass hepatic metabolism. these negative outcomes apparently explain the termination of the further development of ave0118.
Gap-junction therapy
Conduction disturbances are associated with many forms of cardiac arrhythmia, including aF. Conduction abnormalities in the heart can occur as a consequence of disturbances in sodiumchannel or calciumchannel activity, gapjunction abnormalities (impairing cell-cell communications), and structural changes in the myo cardium. 96 Gap junctions-comprised of proteins called connexins (Cx)-are complexes that connect myocardial cells through lowresistance pathways. Cx40, Cx43, and Cx45 are found in the human heart. Cx40 is commonly recognized as a potential target for atrialspecific treat ment of aF because it is found in atrial, but not ventri cular, myocardium. 97 Cx40 is, however, present in the ventricular conduction system. f o c u s o N at r i a l f i B r i l l at i o N to date, experimental studies have shown that improved conduction with the gapjunction modulator rotigaptide may exert antiarrhythmic action in some aF pathologies (models of chronic mitral regurgitation aF and acute ischemia aF), but not others (models of heart failure or atrial tachypacing). 98, 99 GaP134-a dipeptide that behaves similarly to rotigaptide by specifically enhancing gapjunction conductance-has been shown to improve conduction and to reduce inducibility of aF in canine experimental models. 100, 101 the clinical applicability of this approach is yet to be determined.
Intracellular calcium homeostasis
a growing body of evidence implicates abnormal intra cellular calcium homeostasis in the development of aF, and normalization of sarcoplasmic reticulum (sr) calcium release as a potential therapeutic approach. [102] [103] [104] [105] abnormal intracellular calcium handling can promote aF by directly inducing intracellular calciummediated DaD, eaD, and late phase 3 eaDinduced triggered activity, modulating electrical remodeling, and affecting a number of signaling cascades involved in structural remodeling. 105 an increase in spontaneous sr Ca 2+ release, as well as a significant sr calcium leak, have been observed in atrial myocytes isolated from aF patients and dogs with tachypacing induced atrial remodeling. 103, 104 this sr calcium leak may be mediated by protein kinase a hyper phosphorylation and calstabin2 (a ryanodine receptor inhibitory subunit, FKBP12.6). 104 although pharmacological modulation of these arrhythmogenic mechanisms might be of benefit, the challenge is to regulate sr calcium release and intra cellular calcium loading, without compromising myo cardial contractility. ranolazine limits sodium loading, primarily via inhibition of early I Na , and so can also reduce calcium loading associated with conditions that pre dispose to the development of aF, and suppress triggered aF activity induced by DaD, eaD, and late phase 3 eaD. 66 amiodarone has been reported to exert similar actions to ranolazine in both atria and pulmonary veins. 63, 67 other sodiumchannelblocking agents used in the management of aF, including vernakalant, flecainide, propafenone, aZD7009, as well as βblockers, are thought to act in part by modulating calcium homeostasis and suppressing triggered activity.
'Pill-in-the-pocket' approach to therapy the idea of limiting aaD administration to critical times was introduced because the chance of an adverse reaction is more likely with longterm administration of these agents. acute termination of paroxysmal aF with class iC agents has proved to be a reasonable approach in some patients with aF. 18 this has been labeled a 'pill inthepocket' approach. Preliminary results indicate that a single dose of ranolazine (2 g) is effective for this strategy. 106 in addition, ranolazine is safe in patients with structural heart diseases, 87 pointing to a much wider potential applicability of the pillinthepocket approach in patients with aF. shortterm administration of aaDs is also used for maintenance of sinus rhythm following cardioversion (electrically or by catheter radiofrequency oblation) or postoperatively.
4,107 shortterm application of an aaD can be of a greater benefit than risk in some, but not all patients with aF. allcause mortality and the rate of aF recurrence have been shown to be greater in patients treated with amiodarone episodically when compared with those who received amiodarone continu ously (patients with nYHa class iii and iv chronic heart failure were excluded from the study). 108 Upstream therapy the recognition that atrial structural remodeling can lead to the induction of aF 109 has led to the development of 'upstream therapies' , which target arrhythmogenic structural remodeling in the atria, factors that promote such remodeling, or both. 110, 111 structural remodeling encompasses a number of pathological changes, includ ing increased interstitial fibrosis, fibroblast proliferation, dila tation, hypertrophy, pathological collagen accumula tion and its abnormal distribution or redistribution, and is often associated with stretch, oxidative stress, inflamma tion, or ischemia. 112, 113 these factors are in turn induced by, or associated with, hypertension, heart failure, or coronary artery disease.
110-113 studies of drugs designed to directly or indirectly mitigate these precipitating factors, such as aCe inhibitors, angiotensin ii receptor blockers (arBs), omega3 polyunsaturated fatty acids, and statins, have yielded variable results. 110, 111, [114] [115] [116] [117] the precise value of upstream therapy in the treatment of aF varies sub stantially by aF pathology. 111, [116] [117] [118] Preoperative statin and omega3 therapy has been consistently associated with a reduction in postoperative aF.
119-121 a number of clinical studies have indicated that arBs and statins might be of particular benefit for patients with aF and severe ventricular dysfunction and heart failure, [122] [123] [124] but not in those without heart disease. 114, 125, 126 most of the current clinical data on upstream aF therapy are, however, derived from observational studies that were not sufficiently powered, and these findings do not warrant rejection or widespread use of any of the approaches.
111,115-117 the results of several large rando mized placebocontrolled trials are now available. in the GissiaF trial, 114 treatment with the arB val sartan did not reduce the recurrence of aF (only 8% of the enrolled patients had chronic heart failure or lv systolic dysfunction). in another large clinical trial (aCtivei), the arB irbesartan also did not substantially reduce the composite of stroke, myocardial infarction, and vascu lar death in patients with aF and hypertension, but this agent was associated with a reduced rate of hospitaliza tion from heart failure.
127 several large, rando mized placebo controlled trials testing the antiaF efficacy of various types of upstream therapy are underway, includ ing studies assessing antiarrhythmic ability of omega3 acid ethyl esters 115 and olmesartan (the antiPaF trial) 128 in the prevention of recurrence of paroxysmal aF. interestingly, because atria commonly develop structural remodeling to a greater extent than do the ventricles, [129] [130] [131] [132] [133] structural remodeling is a potential atrialselective target for upstream therapy of aF.
134 r E V i E W s 91, 92 may encourage a change of focus in the management of aF, from electrocardiographicallyderived measures (that is, rhythm control and rate control) toward more general end points (such as morbidity and mortality). 138 this novel paradigm is related to the fact that the positive outcomes with dronedarone can be achieved in spite of the rather limited ability of this agent to maintain sinus rhythm. in the combined analysis of euriDis and aDonis, aF recurrence (after 1 year of followup) occurred in 64% patients randomly assigned to dronedarone, as compared with 75% patients taking placebo. 89 several major questions about the pharmacological management of patients with aF need to be addressed in future studies. Because the primary end point of atHena was unique (time to first cardiovascular hospitali zation or death), future studies need to deter mine if dronedarone is superior to the other aaDs in prolonging survival free of cardiovascular hospitalization. of note, secondary analysis of data from DiamonD 137 suggests that dofetilide reduces hospitalization in patients with aF and chronic heart failure without improving all cause mortality. in addition, amiodarone significantly reduced arrhythmic death compared with placebo in patients with myocardial infarction (lv ejection frac tion ≤40%), but did not improve allcause mortality in emiat 139 and Camiat. 140 the introduction of atrialselective sodiumchannel blockade for the management of aF needs to be further explored and developed as an approach to achieving safe and effective rhythm control. 32, 141 available studies suggest that although novel agents demonstrating antiaF efficacy are multiple ion channel blockers, they potently inhibit early I Na (for example, vernakalant, dronedarone, aZD7009, ranolazine) 34, 35, 55, 142 and most, if not all, are atrialselective I Na blockers. we have reviewed this subject elsewhere. 32 studies have revealed a unique synergism when predominantly inactivatedstate and activatedstate I Na blockers are combined. the combination of longterm therapy with amiodarone 63 and acute administration of ranolazine, 55 both of which are atrialselective ion channel blockers, resulted in a profound atrialselective usedependent inhibition of I Na and depression of I Na dependent parameters in isolated canine atria, leading to a potent effect of the drug combination for the preven tion of aF. 143 studies of the molecular differences between atrial and ventricular sodiumchannels are needed to enable us to better understand the basis for atrial selec tivity of pharmacological agents and design ever more selective drugs. experimental observations suggest that studies specifically designed to evaluate the potential clinical role of atrialselective sodiumchannel blockers, such as ranolazine and amiodarone, as anti arrhythmics are warranted.
Conclusions
the ultimate goal of aF therapy is to improve patient qualityoflife and reduce mortality. ongoing research aimed at development of new pharmacological strat egies for the management of aF includes a wide range of approaches, targeting both aFrelated electrical and nonelectrical (intracardiac and extracardiac) abnormali ties. while success to date has been modest, the identi fication of atrialselective agents and targets, as well as the development of upstream therapies, hold promise for the development of effective and safe new treatments.
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